BioVie/$BIVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioVie
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Ticker
$BIVI
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
14
ISIN
US09074F4054
Website
BioVie Metrics
BasicAdvanced
$22M
-
-$1.66
1.15
-
Price and volume
Market cap
$22M
Beta
1.15
52-week high
$4.99
52-week low
$0.62
Average daily volume
671K
Financial strength
Current ratio
9.315
Quick ratio
9.092
Long term debt to equity
1.355
Total debt to equity
1.679
Interest coverage (TTM)
-25.00%
Management effectiveness
Return on assets (TTM)
-42.51%
Return on equity (TTM)
-93.23%
Valuation
Price to book
1.01
Price to tangible book (TTM)
1.04
Price to free cash flow (TTM)
-0.796
Growth
Earnings per share change (TTM)
-82.58%
3-year earnings per share growth (CAGR)
-70.82%
What the Analysts think about BioVie
Analyst ratings (Buy, Hold, Sell) for BioVie stock.
BioVie Financial Performance
Revenues and expenses
BioVie Earnings Performance
Company profitability
BioVie News
AllArticlesVideos
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
GlobeNewsWire·4 weeks ago
BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·1 month ago
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioVie stock?
BioVie (BIVI) has a market cap of $22M as of June 13, 2025.
What is the P/E ratio for BioVie stock?
The price to earnings (P/E) ratio for BioVie (BIVI) stock is 0 as of June 13, 2025.
Does BioVie stock pay dividends?
No, BioVie (BIVI) stock does not pay dividends to its shareholders as of June 13, 2025.
When is the next BioVie dividend payment date?
BioVie (BIVI) stock does not pay dividends to its shareholders.
What is the beta indicator for BioVie?
BioVie (BIVI) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.